Clinical follow-up of hydroxyurea-treated adults with sickle cell disease

Acta Haematologica

Volumn 125, Issue 3, 2011, Pages 145-152

  Nzouakou, Ruben ^a,g   Bachir, Dora ^a   Lavaud, Anne ^a   Habibi, Anoosha ^a   Lee, Ketty ^a   Lionnet, François ^e   Hulin, Anne ^d   Jouault, Hélène ^b   Préhu, Claude ^c   Roudot Thoraval, Françoise ^e   Girot, Robert ^e   Galactéros, Frédéric ^a,f  

^a Sickle Cell Disease Center   (France)

^b Laboratories of Hematology   (France)

^c Laboratories of Biochemistry   (France)

^d Laboratories of Pharmacology and Toxicology   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f FACULTÉ DE MÉDECINE   (France)

^g HENRI MONDOR HOSPITAL   (France)

Author keywords

Hydroxyurea, safety; Hydroxyurea, tolerance; Sickle cell disease

Indexed keywords

HYDROXYUREA;

ADOLESCENT; AMENORRHEA; ANEMIA; ARTICLE; AVASCULAR NECROSIS; BLEEDING; BODY MASS; BODY WEIGHT; CHILD; COHORT ANALYSIS; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DRY SKIN; DYSURIA; ERECTILE DYSFUNCTION; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; LEG ULCER; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEPTIC SHOCK; SICKLE CELL ANEMIA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYUREA; LEG ULCER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650641181     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322248     Document Type: Article

References (31)

1. Galacteros F: Sickle cell disease pathophysiology: from theoretical to practical aspects (in French). Rev Prat 2004; 54: 1534-1542. (Pubitemid 39312189)
2. Bunn HF: Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337: 762-769. (Pubitemid 27417977)
3. Ohene-Frempong K: Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. Semin Hematol 1991; 28: 213-219.
4. Sears DA, Udden MM: Splenic infarction, splenic sequestration, and functional hyposplenism in hemoglobin S-C disease. Am J Hematol 1985; 18: 261-268. (Pubitemid 15131986)
5. Mallouh AA, Qudah A: Acute splenic sequestration together with aplastic crisis caused by human parvovirus B19 in patients with sickle cell disease. J Pediatr 1993; 122: 593-595. (Pubitemid 23093586)
6. Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, Pegelow CH, Vichinsky E: Clinical events in the first decade in a cohort of infants with sickle cell disease: Cooperative Study of Sickle Cell Disease. Blood 1995; 86: 776-783.
7. Haynes J Jr, Kirkpatrick MB: The acute chest syndrome of sickle cell disease. Am J Med Sci 1993; 305: 326-330. (Pubitemid 23145449)
8. Moriarty BJ, Acheson RW, Condon PI, Serjeant GR: Patterns of visual loss in untreated sickle cell retinopathy. Eye 1988; 2(pt 3):330- 335.
9. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, Wethers DL, Smith J, Kinney TR: Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000; 342: 83-89. (Pubitemid 30036599)
10. Ballas SK: Sickle cell anaemia: progress in pathogenesis and treatment. Drugs 2002; 62: 1143-1172. (Pubitemid 34587570)
11. Styles LA, Vichinsky EP: New therapies and approaches to transfusion in sickle cell disease in children. Curr Opin Pediatr 1997; 9: 41-45. (Pubitemid 27149021)
12. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia: Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332: 1317-1322.
13. Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, Mc- Mahon RP, Castro O, Orringer EP: Hydroxyurea and sickle cell anemia: clinical utility of a myelosuppressive 'switching' agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) 1996; 75: 300-326.
14. Veith R, Galanello R, Papayannopoulou T, Stamatoyannopoulos G: Stimulation of Fcell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea. N Engl J Med 1985; 313: 1571-1575. (Pubitemid 16177396)
15. Maier-Redelsperger M, de Montalembert M, Flahault A, Neonato MG, Ducrocq R, Masson MP, Girot R, Elion J: Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients: the French Study Group on Sickle Cell Disease. Blood 1998; 91: 4472-4479. (Pubitemid 28270293)
16. Odievre MH, Bony V, Benkerrou M, Lapoumeroulie C, Alberti C, Ducrocq R, Jacqz-Aigrain E, Elion J, Cartron JP: Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease. Haematologica 2008; 93: 502-510.
17. Canalli AA, Franco-Penteado CF, Saad ST, Conran N, Costa FF: Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Haematologica 2008; 93: 605-609. (Pubitemid 351536391)
18. Berthaut I, Guignedoux G, Kirsch-Noir F, de Larouziere V, Ravel C, Bachir D, Galacteros F, Ancel PY, Kunstmann JM, Levy L, Jouannet P, Girot R, Mandelbaum J: Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 2008; 93: 988-993. (Pubitemid 351957015)
19. Trent JT, Kirsner RS: Leg ulcers in sickle cell disease. Adv Skin Wound Care 2004; 17: 410- 416.
20. Khouri RK, Upton J: Bilateral lower limb salvage with free flaps in a patient with sickle cell ulcers. Ann Plast Surg 1991; 27: 574-576.
21. Reindorf CA, Walker-Jones D, Adekile AD, Lawal O, Oluwole SF: Rapid healing of sickle cell leg ulcers treated with collagen dressing. J Natl Med Assoc 1989; 81: 866-868. (Pubitemid 19204451)
22. Sirieix ME, Debure C, Baudot N, Dubertret L, Roux ME, Morel P, Francès C, Loubeyres S, Beylot C, Lambert D, Humbert P, Gauthier O, Dandurand M, Guillot B, Vaillant L, Lorette G, Bonnetblanc JM, Lok C, Denoeux JP: Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol 1999; 135: 818-820. (Pubitemid 29330806)
23. Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi C, James AH, Laraque D, Mendez M, Montoya CJ, Pollock BH, Robinson L, Scholnik AP, Schori M: National institutes of health consensus development conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008; 148: 932-938. (Pubitemid 351860825)
24. Dover GJ, Humphries RK, Moore JG, Ley TJ, Young NS, Charache S, Nienhuis AW: Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood 1986; 67: 735-738. (Pubitemid 16130265)
25. Alvarez O, Montane B, Lopez G, Wilkinson J, Miller T: Early blood transfusions protect against microalbuminuria in children with sickle cell disease. Pediatr Blood Cancer 2006; 47: 71-76. (Pubitemid 43787911)
26. Yan JH, Ataga K, Kaul S, Olson JS, Grasela DM, Gothelf S, Kutlar A, Orringer E: The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. J Clin Pharmacol 2005; 45: 434-445. (Pubitemid 40490416)
27. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M: Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003; 289: 1645-1651. (Pubitemid 37430269)
28. Hackney AC, Hezier W, Gulledge TP, Jones S, Strayhorn D, Busby M, Hoffman E, Orringer EP: Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clin Sci (Lond) 1997; 92: 481-486. (Pubitemid 27214207)
29. Platt OS: Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 2008; 358: 1362-1369.
30. Valafar H, Valafar F, Darvill A, Albersheim P, Kutlar A, Woods KF, Hardin J: Predicting the effectiveness of hydroxyurea in individual sickle cell anemia patients. Artif Intell Med 2000; 18: 133-148. (Pubitemid 30050743)
31. Saleh AW, Hillen HF, Duits AJ: Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol 1999; 102: 31-37. (Pubitemid 29417701)